- Home
- IFBD vs NXTC Comparison
IFBD vs NXTC Comparison
Compare IFBD & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFBD
- NXTC
- Stock Information
- Founded
- IFBD 2001
- NXTC 2015
- Country
- IFBD China
- NXTC United States
- Employees
- IFBD N/A
- NXTC N/A
- Industry
- IFBD Computer Software: Prepackaged Software
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- IFBD Technology
- NXTC Health Care
- Exchange
- IFBD Nasdaq
- NXTC Nasdaq
- Market Cap
- IFBD 8.4M
- NXTC 9.3M
- IPO Year
- IFBD 2021
- NXTC 2019
- Fundamental
- Price
- IFBD $1.10
- NXTC $0.41
- Analyst Decision
- IFBD
- NXTC Strong Buy
- Analyst Count
- IFBD 0
- NXTC 2
- Target Price
- IFBD N/A
- NXTC $3.50
- AVG Volume (30 Days)
- IFBD 100.0K
- NXTC 178.3K
- Earning Date
- IFBD 01-01-0001
- NXTC 05-01-2025
- Dividend Yield
- IFBD N/A
- NXTC N/A
- EPS Growth
- IFBD N/A
- NXTC N/A
- EPS
- IFBD N/A
- NXTC N/A
- Revenue
- IFBD $1,437,848.00
- NXTC N/A
- Revenue This Year
- IFBD N/A
- NXTC N/A
- Revenue Next Year
- IFBD N/A
- NXTC N/A
- P/E Ratio
- IFBD N/A
- NXTC N/A
- Revenue Growth
- IFBD 413.52
- NXTC N/A
- 52 Week Low
- IFBD $0.89
- NXTC $0.22
- 52 Week High
- IFBD $4.71
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- IFBD 47.28
- NXTC 45.41
- Support Level
- IFBD $1.05
- NXTC $0.34
- Resistance Level
- IFBD $1.69
- NXTC $0.47
- Average True Range (ATR)
- IFBD 0.11
- NXTC 0.06
- MACD
- IFBD 0.03
- NXTC 0.01
- Stochastic Oscillator
- IFBD 24.31
- NXTC 39.66
About IFBD Infobird Co. Ltd
Infobird Co Ltd is engaged in developing and providing customer engagement cloud-based services. It software-as-a-service provider of AI-powered, or artificial intelligence-enabled, customer engagement solutions in China. It provides holistic software solutions to help corporate clients proactively deliver and manage end-to-end customer engagement activities at all stages of the sales process, including pre-sales and sales activities, and post-sales customer support. It also offers AI-powered cloud-based sales force management software, including intelligent quality inspection and intelligent training software to help clients monitor, benchmark, and improve the performance of agents.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.